Being tested
Cell therapies and tolerisation: reduce relapses and new lesions in relapsing and progressive MS
relapsing and progressive MS · Cell therapies and tolerisation
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 10
- Running now
- 1
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 10
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 10
These linked trials do not set the status.
- MESCAMSResult in a paper, not read yet
Phase 2 · 2015 · Not randomised
- ATX-MS-1467 in Multiple SclerosisNo result found
Phase 2 · 2014 · Not randomised
- CMM-EMStopped, other reason
Phase 2 · 2010 · Not randomised
Phase 1/2 · 2026 · Not randomised
- MESEMSStopped, other reason
Phase 1/2 · 2015 · Placebo-controlled
- STREAMSMissed main goal
Phase 1/2 · 2013 · Placebo-controlled
- MESEMSResult in a paper, not read yet
Phase 1/2 · 2012 · Placebo-controlled
- Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple SclerosisNo result found
Phase 1/2 · 2011 · Placebo-controlled
- TOLERVIT-MSResult in a paper, not read yet
Phase 1 · 2017 · Not randomised
Phase 1 · 2012 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Being tested
Related hypotheses
- Cell therapies and tolerisation: reduce relapses and new lesions in early MS (CIS or RIS)
- Cell therapies and tolerisation: reduce relapses and new lesions in primary progressive MS
- Cell therapies and tolerisation: reduce relapses and new lesions in relapsing MS
- Cell therapies and tolerisation: reduce relapses and new lesions in secondary progressive MS
- Cell therapies and tolerisation: reduce relapses and new lesions in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error